Switching and withdrawing hormonal agents for castration-resistant prostate cancer. (Q38309205)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

review article

1 reference

title

Switching and withdrawing hormonal agents for castration-resistant prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Joaquin Mateo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Zafeiris Zafeiriou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Alan D Smith

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Roberta Ferraldeschi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Johann S de Bono

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

37-47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25563847%20AND%20SRC:MED&resulttype=core&format=json

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

The changing therapeutic landscape of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Development of prostate cancer treatment: the good news

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Abiraterone in metastatic prostate cancer without previous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Androgen receptor antagonists (antiandrogens): structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Enzalutamide in metastatic prostate cancer before chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

ARN-509: a novel antiandrogen for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Molecular biology of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

The mutational landscape of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Pleiotropic functional properties of androgen receptor mutants in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

The androgen receptor gene mutations database: 2012 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Androgen receptor coregulators and their involvement in the development and progression of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Alternative antiandrogen therapy in patients with castration‐resistant prostate cancer: A single‐center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Overcoming mutation-based resistance to antiandrogens with rational drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Androgen receptor splice variants determine taxane sensitivity in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Gastric perforation secondary to regression of lung adenocarcinoma after gefitinib treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Abiraterone acetate is well tolerated without concomitant use of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Designer antiandrogens join the race against drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Androgen receptor signaling in prostate cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Antiandrogen withdrawal syndrome with nilutamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

A canonical structure for the ligand-binding domain of nuclear receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Antiandrogen withdrawal syndrome with cyproterone acetate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Prostate specific antigen and prostate acid phosphatase declines after estramustine phosphate withdrawal: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Abiraterone--what is wrong with the adrenal glands?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.345

Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone

31 March 2020

1 reference

12 December 2020

Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence

1 reference

12 December 2020

Efficacy of low-dose dexamethasone in castration-refractory prostate cancer

1 reference

12 December 2020

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

12 December 2020

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

1 reference

12 December 2020

A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy

1 reference

12 December 2020

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

12 December 2020

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

1 reference

12 December 2020

A canonical structure for the ligand-binding domain of nuclear receptors

1 reference

12 December 2020

Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.

1 reference

12 December 2020

Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft

1 reference

12 December 2020

Androgen receptor mutations in prostate cancer

1 reference

12 December 2020

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers

1 reference

12 December 2020

Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Withdrawal phenomenon with the antiandrogen casodex

1 reference

12 December 2020